X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3061) 3061
Book Chapter (58) 58
Publication (19) 19
Dissertation (17) 17
Conference Proceeding (4) 4
Reference (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sunitinib (2855) 2855
science & technology (2214) 2214
life sciences & biomedicine (2170) 2170
humans (1954) 1954
oncology (1445) 1445
male (1034) 1034
female (1018) 1018
middle aged (852) 852
carcinoma, renal cell - drug therapy (819) 819
indoles - therapeutic use (816) 816
pyrroles - therapeutic use (812) 812
antineoplastic agents - therapeutic use (805) 805
kidney neoplasms - drug therapy (771) 771
aged (748) 748
renal cell carcinoma (629) 629
sorafenib (594) 594
treatment outcome (560) 560
adult (558) 558
cancer (552) 552
metastasis (526) 526
kidney neoplasms - pathology (525) 525
indoles - adverse effects (450) 450
pyrroles - adverse effects (450) 450
carcinoma, renal cell (424) 424
care and treatment (423) 423
indoles - administration & dosage (414) 414
animals (413) 413
pyrroles - administration & dosage (412) 412
antineoplastic agents (398) 398
pharmacology & pharmacy (390) 390
antimitotic agents (377) 377
carcinoma, renal cell - pathology (373) 373
antineoplastic agents - adverse effects (360) 360
bevacizumab (336) 336
vascular endothelial growth factor (324) 324
indoles - pharmacology (314) 314
pyrroles - pharmacology (312) 312
aged, 80 and over (310) 310
disease-free survival (301) 301
angiogenesis inhibitors - therapeutic use (288) 288
medicine & public health (288) 288
urologic and male genital diseases (287) 287
retrospective studies (275) 275
analysis (274) 274
protein kinase inhibitors - therapeutic use (274) 274
tumors (271) 271
tyrosine (266) 266
angiogenesis (261) 261
antineoplastic agents - administration & dosage (252) 252
prognosis (249) 249
everolimus (244) 244
drug therapy (243) 243
neoplasm metastasis (241) 241
urology & nephrology (240) 240
carcinoma, renal cell - secondary (239) 239
imatinib (234) 234
mice (227) 227
niacinamide - analogs & derivatives (226) 226
antineoplastic agents - pharmacology (225) 225
chemotherapy (219) 219
research (214) 214
tyrosine kinase inhibitor (195) 195
kidney cancer (194) 194
cell line, tumor (193) 193
hematology, oncology and palliative medicine (187) 187
carcinoma, renal cell - mortality (183) 183
kidney neoplasms - mortality (179) 179
gastrointestinal stromal tumors - drug therapy (177) 177
targeted therapy (174) 174
metastatic renal cell carcinoma (172) 172
pazopanib (172) 172
antineoplastic combined chemotherapy protocols - therapeutic use (170) 170
female genital diseases and pregnancy complications (170) 170
kinases (159) 159
patients (158) 158
tyrosine kinase inhibitors (158) 158
angiogenesis inhibitors (155) 155
health aspects (150) 150
urology (148) 148
pyrimidines - therapeutic use (144) 144
drug administration schedule (137) 137
vegf (137) 137
clinical trials (136) 136
angiogenesis inhibitors - adverse effects (135) 135
cancer therapies (135) 135
phenylurea compounds (134) 134
protein-tyrosine kinases - antagonists & inhibitors (134) 134
development and progression (132) 132
protein kinase inhibitors - pharmacology (132) 132
temsirolimus (131) 131
protein kinase inhibitors - adverse effects (130) 130
angiogenesis inhibitors - pharmacology (126) 126
drug resistance, neoplasm (125) 125
dose-response relationship, drug (123) 123
imatinib mesylate (123) 123
neoplasm staging (123) 123
metastases (122) 122
sunitinib - therapeutic use (122) 122
risk factors (121) 121
cancer research (120) 120
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2969) 2969
German (50) 50
Japanese (47) 47
French (37) 37
Korean (25) 25
Spanish (25) 25
Russian (23) 23
Chinese (16) 16
Czech (10) 10
Portuguese (10) 10
Turkish (7) 7
Polish (5) 5
Slovak (4) 4
Hungarian (3) 3
Italian (2) 2
Catalan (1) 1
Croatian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 03/2019, Volume 380, Issue 12, pp. 1116 - 1127
Among patients with advanced renal-cell carcinoma, overall survival and progression-free survival were longer among patients who received pembrolizumab and... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Axitinib - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Adult | Female | Axitinib - adverse effects | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Survival Rate | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Sunitinib - adverse effects | Administration, Intravenous | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Intention to Treat Analysis | Aged | Kidney Neoplasms - drug therapy | Axitinib | Dosage and administration | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Risk groups | Metastasis | Cancer therapies | Evidence-based medicine | Metastases | Pembrolizumab | Kidney cancer | Antitumor activity | Death | Blood pressure | Vascular endothelial growth factor | Drug dosages | Clear cell-type renal cell carcinoma | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2019, Volume 380, Issue 12, pp. 1103 - 1115
Journal Article
Journal Article
Journal Article
Health technology assessment (Winchester, England), ISSN 2046-4924, 09/2018, Volume 22, Issue 49, pp. 1 - 326
Journal Article